Tumor-Associated Antigens Modified with Alpha-Gal Epitopes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments, including immunotherapies, face challenges in effectively stimulating a potent immune response against tumor cells due to weak antigen presentation and the risk of autoimmune reactions, particularly with whole tumor cell vaccines and purified tumor-specific antigen (TAA) proteins or peptides, which often result in poor immunogenicity and limited scalability.

Innovation Solution

Modification of TAA proteins or peptides by adding αGal epitopes to facilitate the formation of immunocomplexes with natural anti-αGal antibodies, enhancing antigen presentation and immune response through FcγR-mediated capture and activation of antigen-presenting cells, thereby inducing a humoral and cellular immune response against tumor cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If whole tumor cell vaccines are used, then relevant tumor-associated antigens are expressed, but antigen presentation is weak and autoimmune reactions may occur

Engineering Contradiction:

Improveantigen expressionVSAvoidimmune response quality

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent extracts and purifies specific tumor-associated antigens from whole tumor cells, separating the useful immunogenic components from the harmful non-specific components. This extraction process allows the use of defined antigen preparations that maintain tumor specificity while eliminating the weak antigen presentation and autoimmune stimulation issues associated with whole cell vaccines.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality modification by selectively modifying the purified TAA proteins through glycosylation engineering to introduce αGal epitopes at specific locations. This localized modification enhances the immunogenicity of specific regions of the antigen without affecting the overall specificity, thereby improving immune response quality while maintaining antigen expression.

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If purified TAA proteins are used, then treatment specificity is improved, but immunogenicity is poor

Engineering Contradiction:

Improvetreatment specificityVSAvoidimmunogenicity

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent changes the biochemical parameters of the purified TAA proteins by introducing αGal epitopes through glycosylation modification. This parameter change (addition of carbohydrate structures) significantly enhances the immunogenicity of the TAA proteins while preserving their tumor-specificity, as the epitope modification does not alter the protein's recognition by tumor-specific T cells.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite TAA proteins by combining the original TAA protein structure with αGal epitope carbohydrate moieties. This composite structure integrates the specificity of the protein with the enhanced immunogenicity of the glycosylated epitopes, achieving both treatment specificity and improved immunogenicity simultaneously.

Inventive Principle:

Principle #40Composite materials

3Reliability

If natural anti-αGal antibodies are utilized, then immunocomplex formation is enhanced, but autoimmune reactions against normal cells may occur

Engineering Contradiction:

Improveimmune response strengthVSAvoidautoimmune reaction risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality modification by selectively introducing αGal epitopes only to the purified TAA proteins that are expressed by tumor cells, rather than to all cellular proteins. This localized epitope addition ensures that the enhanced immunogenicity is confined to tumor-specific antigens, thereby strengthening the immune response against tumors while avoiding widespread autoimmune reactions against normal cells.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the immunogenicity of TAA proteins or peptides, promoting a strong and specific immune response against tumor cells while minimizing autoimmune reactions, offering a scalable and reproducible therapeutic method for cancer treatment.

Implementation Method 1

Modification of TAA proteins or peptides by adding αGal epitopes to facilitate the formation of immunocomplexes with natural anti-αGal antibodies

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

enhancing antigen presentation and immune response through FcγR-mediated capture and activation of antigen-presenting cells

Methodology Applied

Scientific EffectFcγR-mediated capture:

Data Source

PatentUS9090643B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes

Publication Date: 2015.07.28 LUMOS PHARMA INC

AI summary

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.